Demographic overview of control and CFS patients.
收藏数据链接：
官方服务：
资源简介：
Data are expressed as mean ± SD.***p
应用场景：
创建时间：
2015-12-02
相关数据集
Data_Sheet_1_Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study.PDF
Introduction: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disease with high symptom burden, of unknown etiology, with no established treatment. We observed patients with long-stan
NIAID Data Ecosystem30
Demographic information for autism and control groups.
1p value for gender was computed using the Fisher exact statistic; other p values were computed from the two-sample t test.
NIAID Data Ecosystem20
Table_2_Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study.docx
Introduction: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disease with high symptom burden, of unknown etiology, with no established treatment. We observed patients with long-stan
NIAID Data Ecosystem10
Baseline demographic and clinical data.
Data are N (%) unless otherwise stated. APT = adaptive pacing therapy, CBT = cognitive behaviour therapy, GET = graded exercise therapy, SMC = specialist medical care alone, ME = myalgic enc
NIAID Data Ecosystem20
Physical, mental, emotional, social, and occupational functioning among persons with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-like illness after coronavirus disease 2019 (COVID-19), persons with ME/CFS-like illness without prior COVID-19, and persons without ME/CFS-like illness Kaiser Permanente Northern California, 2022.
Physical, mental, emotional, social, and occupational functioning among persons with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-like illness after coronavirus disease 2019 (COVID-19),
NIAID Data Ecosystem10
